Toward Repurposing Ciclopirox as an Antibiotic against Drug-Resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Antibiotic-resistant infections caused by gram-negative bacteria are a major healthcare concern. Repurposing drugs circumvents the time and money limitations associated with developing new antimicrobial agents needed to combat these antibiotic-resistant infections. Here we identified the off-patent antifungal agent, ciclopirox, as a candidate to repurpose for antibiotic use. To test the efficacy of ciclopirox against antibiotic-resistant pathogens, we used a curated collection of Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates that are representative of known antibiotic resistance phenotypes. We found that ciclopirox, at 5-15 µg/ml concentrations, inhibited bacterial growth regardless of the antibiotic resistance status. At these same concentrations, ciclopirox reduced growth of Pseudomonas aeruginosa clinical isolates, but some of these pathogens required higher ciclopirox concentrations to completely block growth. To determine how ciclopirox inhibits bacterial growth, we performed an overexpression screen in E. coli. This screen revealed that galE, which encodes UDP-glucose 4-epimerase, rescued bacterial growth at otherwise restrictive ciclopirox concentrations. We found that ciclopirox does not inhibit epimerization of UDP-galactose by purified E. coli GalE; however, ΔgalU, ΔgalE, ΔrfaI, or ΔrfaB mutant strains all have lower ciclopirox minimum inhibitory concentrations than the parent strain. The galU, galE, rfaI, and rfaB genes all encode enzymes that use UDP-galactose or UDP-glucose for galactose metabolism and lipopolysaccharide (LPS) biosynthesis. Indeed, we found that ciclopirox altered LPS composition of an E. coli clinical isolate. Taken together, our data demonstrate that ciclopirox affects galactose metabolism and LPS biosynthesis, two pathways important for bacterial growth and virulence. The lack of any reported fungal resistance to ciclopirox in over twenty years of use in the clinic, its excellent safety profiles, novel target(s), and efficacy, make ciclopirox a promising potential antimicrobial agent to use against multidrug-resistant problematic gram-negative pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Repurposing this drug toward drug-resistant bacterial species has also proven to be promising (Carlson-Banning et al., 2013).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Carlson-Banning et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Construction of Escherichia coli K‐12 in‐frame, single‐gene knockout mutants: the Keio collection
Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., & Mori, H. (2006) · Molecular Systems Biology · doi:10.1038/msb4100050 · Cited by 7,858 · cited 7×
“Only overexpression of glf or galE is not lethal (Figure 6A) [30,39].”
BackgroundMethodInfluentialUse of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
Studier, F. W., & Moffatt, B. A. (1986) · Journal of Molecular Biology · doi:10.1016/0022-2836(86)90385-2 · Cited by 6,320 · cited 1×
“coli from Epicentre Biotechnologies (Madison WI), MG1655 and BL21(DE3) [81].”
BackgroundBad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958 · cited 3×
“presently in development are effective against them [4,5].”
BackgroundMethodThe Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Raetz, C. R. H., & Whitfield, C. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135414 · Cited by 4,404
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724 · cited 2×
“and 70% of all intensive care unit infections [4].”
BackgroundGlobal Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777 · cited 4×
“Repurposing already approved therapies for alternative uses saves both time and money [7].”
BackgroundInfluentialCarbon catabolite repression in bacteria: many ways to make the most out of nutrients
Görke, B., & Stülke, J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1932 · Cited by 1,701 · cited 4×
“metabolizing it through the Emden-Meyerhof-Parnas (EMP) pathway, and repress other sugar metabolism pathways when it is present [61,62].”
BackgroundMethodInfluentialHospital-Acquired Infections Due to Gram-Negative Bacteria
Peleg, A. Y., & Hooper, D. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0904124 · Cited by 1,495
Kitagawa, M., Ara, T., Arifuzzaman, M., Ioka-Nakamichi, T., Inamoto, E., Toyonaga, H., & Mori, H. (2006) · DNA Research · doi:10.1093/dnares/dsi012 · Cited by 1,388
Snitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863 · cited 1×
“Enterobacteriaceae producing extended-spectrum b-lactamases and carbapenemases cause nosocomial outbreaks that are spreading globally [6,56].”
BackgroundStaphylococcus aureus CC398: Host Adaptation and Emergence of Methicillin Resistance in Livestock
Price, L. B., Stegger, M., Hasman, H., Aziz, M., Larsen, J., Andersen, P. S., Pearson, T., Waters, A. E., Foster, J. T., Schupp, J., et al. (2012) · mBio · doi:10.1128/mbio.00305-11 · Cited by 858
Regulated virulence controls the ability of a pathogen to compete with the gut microbiota
Kamada, N., Kim, Y.-G., Sham, H. P., Vallance, B. A., Puente, J. L., Martens, E. C., & Núñez, G. (2012) · Science · doi:10.1126/science.1222195 · Cited by 682
Gunn, J. S., Lim, K. B., Krueger, J., Kim, K., Guo, L., Hackett, M., & Miller, S. I. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00757.x · Cited by 655 · cited 1×
“In conjunction with Ugd, the arn operon-encoded proteins synthesize 4-amino-4-deoxy-a-L-arabinose to incorporate it into the Lipid A structure, which alters the overall membrane charge [44,78,79].”
BackgroundPathways of O-glycan biosynthesis in cancer cells
Brockhausen, I. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00170-1 · Cited by 583 · cited 2×
“Galactose and N-acetylglucosamine are required to form O-glycan core structures in eukaryotic cells [74].”
BackgroundGermanier, R., & Fiirer, E. (1975) · Journal of Infectious Diseases · doi:10.1093/infdis/131.5.553 · Cited by 523 · cited 1×
“A vaccine against Salmonella enterica serovar Typhi, the only live attenuated bacterial vaccine in the United States, is a galE mutant [46,59].”
BackgroundIron availability and infection
Weinberg, E. D. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.07.002 · Cited by 516 · cited 1×
“During a bacterial infection, however, the human host defense system actively sequesters free iron to limit pathogen growth [26].”
BackgroundRole of Iron in Bacterial Infection
Bullen, J. J., Rogers, H. J., & Griffiths, E. (1978) · Modern Aspects of Electrochemistry · doi:10.1007/978-3-642-66956-9_1 · Cited by 492 · cited 1×
“Indeed, unbound ferric iron concentrations in plasma, lymph, and external secretions of milk and bronchial mucus have been reported to be ,10(218) M, which is far below the 50 mM needed to rescue bacterial growth from ciclopirox inhibition [27].”
BackgroundRole of reactive oxygen species in antibiotic action and resistance
Dwyer, D. J., Kohanski, M. A., & Collins, J. J. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.06.018 · Cited by 484 · cited 2×
“This lack of sensitization is consistent with the mechanism of action of some bacteriostatic antibiotics [28] and agrees with the above time-kill curve results at sub-inhibitory ciclopirox concentrations.”
ResultLipopolysaccharide: Biosynthetic pathway and structure modification
Wang, X., & Quinn, P. J. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.06.002 · Cited by 471 · cited 1×
“coli also uses iron to signal modifications to the lipid A structure, an essential component of the LPS responsible for the toxic effects of gram-negative infections on the immune system [77].”
BackgroundGunn, J. S., Ryan, S. S., van Velkinburgh, J. C., Ernst, R. K., & Miller, S. I. (2000) · Infection and Immunity · doi:10.1128/.68.11.6139-6146.2000 · Cited by 398
Experimental Identification and Quantification of Glucose Metabolism in Seven Bacterial Species
Fuhrer, T., Fischer, E., & Sauer, U. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.5.1581-1590.2005 · Cited by 393 · cited 2×
“metabolizing it through the Emden-Meyerhof-Parnas (EMP) pathway, and repress other sugar metabolism pathways when it is present [61,62].”
BackgroundMethodCollignon, P., Powers, J. H., Chiller, T. M., Aidara‐Kane, A., & Aarestrup, F. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599374 · Cited by 385 · cited 1×
“The World Health Organization lists antibiotic-resistant bacterial infections as an important public health problem [1].”
BackgroundMauldin, P. D., Salgado, C. D., Hansen, I. S., Durup, D. T., & Bosso, J. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01041-09 · Cited by 360 · cited 1×
“[2], resulting in the deaths of approximately 99,000 patients each year [3].”
BackgroundMechanisms Underlying Aberrant Glycosylation of MUC1 Mucin in Breast Cancer Cells
Brockhausen, I., Yang, J., Burchell, J., Whitehouse, C., & Taylor‐Papadimitriou, J. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.607_2.x · Cited by 346 · cited 1×
“In chronic myelogenous leukemia cells and in breast cancer MCF-7 cells, there is an increase in a3sialytranserase activity, which produces shorter, sialylated Oglycans compared to normal myeloid and breast cells [75,76].”
BackgroundLee, H., Hsu, F.-F., Turk, J., & Groisman, E. A. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.13.4124-4133.2004 · Cited by 334 · cited 1×
“resistance is clinically relevant [43,44].”
Evaluation of 16S rDNA-Based Community Profiling for Human Microbiome Research
Jumpstart Consortium Human Microbiome Project Data Generation Working Group (2012) · PLoS ONE · doi:10.1371/journal.pone.0039315 · Cited by 297
Liu, A., Tran, L., Becket, E., Lee, K., Chinn, L., Park, E., Tran, K., & Miller, J. H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-09 · Cited by 286 · cited 1×
“The DrfaC, DrfaD, DrfaG, DrfaP, DrfaQ, and DrfaY LPS pathway mutants had previously been shown to display enhanced sensitivity to other antibiotics compared to the parent BW25113 strain, but the galactose salvage pathway deletions were not affected by the tested antibiotics [40].”
BackgroundCornelis, P., & Matthijs, S. (2002) · Environmental Microbiology · doi:10.1046/j.1462-2920.2002.00369.x · Cited by 278 · cited 1×
“aeruginosa cultures that produce the siderophore, pyoverdin, are yellow-green and strains that produce the virulence factor, pyocyanin, are bluegreen [54,55].”
BackgroundTranscriptional regulation of carbohydrate metabolism in the human pathogen Candida albicans
Askew, C., Sellam, A., Epp, E., Hogues, H., Mullick, A., Nantel, A., & Whiteway, M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000612 · Cited by 260 · cited 1×
“albicans senses galactose directly affects cell morphology, virulence, and pathogenicity [70,71].”
BackgroundSimonsen, L., Taylor, R. J., Young-Xu, Y., Haber, M., May, L., & Klugman, K. P. (2011) · mBio · doi:10.1128/mbio.00309-10 · Cited by 256
Lipid A Modifications in Polymyxin-resistant Salmonella typhimurium
Zhou, Z., Ribeiro, A. A., Lin, S., Cotter, R. J., Miller, S. I., & Raetz, C. R. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106960200 · Cited by 230 · cited 1×
“In conjunction with Ugd, the arn operon-encoded proteins synthesize 4-amino-4-deoxy-a-L-arabinose to incorporate it into the Lipid A structure, which alters the overall membrane charge [44,78,79].”
BackgroundSwick, M. C., Morgan-Linnell, S. K., Carlson, K. M., & Zechiedrich, L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00996-10 · Cited by 219
Self-citationNesper, J., Lauriano, C. M., Klose, K. E., Kapfhammer, D., Kraiß, A., & Reidl, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.1.435-445.2001 · Cited by 208 · cited 2×
“Vibrio cholerae O1 galU mutants also have reduced ability to colonize mouse small intestine [47].”
BackgroundYethon, J. A., Heinrichs, D. E., Monteiro, M. A., Perry, M. B., & Whitfield, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26310 · Cited by 197 · cited 1×
“Instead of adding sugars to the inner core, RfaP phosphorylates heptose I and can affect RfaY and RfaQ functions [42].”
Background(2011) · InTech eBooks · doi:10.5772/683 · Cited by 184
Eberhard, Y., McDermott, S. P., Wang, X., Gronda, M., Venugopal, A., Wood, T. E., Hurren, R., Datti, A., Batey, R. A., Wrana, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209965 · Cited by 183 · cited 2×
“Additionally, ciclopirox is currently in a Phase I clinical trial for treatment of multiple myeloma [14,15].”
BackgroundThe yeast galactose genetic switch is mediated by the formation of a Gal4p–Gal80p–Gal3p complex
Platt, A., & Reece, R. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.14.4086 · Cited by 179 · cited 1×
“cerevisiae uses GAL80 to regulate GAL4, a transcriptional activator of the galactose operon [68].”
BackgroundThe metabolic basis of Candida albicans morphogenesis and quorum sensing.
Han, T.-L., Cannon, R. D., & Villas-Bôas, S. G. (2011) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2011.04.002 · Cited by 173 · cited 1×
“albicans senses galactose directly affects cell morphology, virulence, and pathogenicity [70,71].”
BackgroundWhitfield, C., & Paiment, A. (2003) · Carbohydrate Research · doi:10.1016/j.carres.2003.08.010 · Cited by 166
Ciclopirox: Recent Nonclinical and Clinical Data Relevant to its Use as a Topical Antimycotic Agent
Subissi, A., Monti, D., Togni, G., & Mailland, F. (2010) · Drugs · doi:10.2165/11538110-000000000-00000 · Cited by 164
Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., & Zechiedrich, L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00665-08 · Cited by 161
Self-citationBhat, P. J., & Murthy, T. V. S. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02421.x · Cited by 144 · cited 1×
“albicans and other yeast instead use HGT4 to regulate GAL genes [66,69].”
BackgroundNiewerth, M., Kunze, D., Seibold, M., Schaller, M., Korting, H. C., & Hube, B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1805-1817.2003 · Cited by 144 · cited 5×
“albicans revealed gene expression level changes similar to those exhibited in iron-deprived conditions [17,18].”
BackgroundInfluentialThe galE Gene of Campylobacter jejuni Is Involved in Lipopolysaccharide Synthesis and Virulence
Fry, B. N., Feng, S., Chen, Y.-Y., Newell, D. G., Coloe, P. J., & Korolik, V. (2000) · Infection and Immunity · doi:10.1128/iai.68.5.2594-2601.2000 · Cited by 141
Noncoding RNA control of the making and breaking of sugars
Görke, B., & Vogel, J. (2008) · Genes & Development · doi:10.1101/gad.1717808 · Cited by 122 · cited 1×
“coli to either catabolize galactose or to generate the nucleotide-charged substrates, UDP-galactose or UDP-glucose, depending on cellular needs [35,58].”
BackgroundBreazeale, S. D., Ribeiro, A. A., & Raetz, C. R. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304043200 · Cited by 121
Hoque, M., Hanauske-Abel, H. M., Palumbo, P. E., Saxena, D., Gandolfi, D. D., Park, M. H., Pe’ery, T., & Mathews, M. B. (2009) · Retrovirology · doi:10.1186/1742-4690-6-90 · Cited by 121 · cited 1×
“Indeed, others have suggested repurposing ciclopirox as an anti-human immunodeficiency virus drug [11], an agent to protect against mitochondrial damaged cells [12], and a way to enhance diabetic wound healing [13].”
BackgroundRelationship between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus lactis
Ramos, A., Boels, I. C., de Vos, W. M., & Santos, H. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.1.33-41.2001 · Cited by 112 · cited 1×
“GalE is involved with LPS [45–47] and exopolysaccharide (EPS) formation [38,48].”
BackgroundThe antitumor activity of the fungicide ciclopirox
Zhou, H., Shen, T., Luo, Y., Liu, L., Chen, W., Xu, B., Han, X., Pang, J., Rivera, C. A., & Huang, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25255 · Cited by 106 · cited 1×
“Its effects on galactose metabolism or utilization may help explain why ciclopirox is effective against chronic myeloid leukemia and breast cancer cell lines compared to normal cells [15,73].”
BackgroundMicromethods for the Characterization of Lipid A-Core and O-Antigen Lipopolysaccharide
Marolda, C. L., Lahiry, P., Vinés, E., Saldías, S., & Valvano, M. A. (2006) · Glycobiology Protocols · doi:10.1385/1-59745-167-3:237 · Cited by 98 · cited 2×
“LPS constituents were analyzed by SDS-PAGE as described [51].”
MethodGenomic BLAST: custom-defined virtual databases for complete and unfinished genomes
Cummings, L. M., Riley, L., Black, L., Souvorov, A. E., Resenchuk, S. M., Dondoshansky, I., & Tatusova, T. A. (2002) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2002.tb11426.x · Cited by 96 · cited 3×
“Sequence identity was confirmed using genomic microbial BLAST and the Ribosomal Database Project (RDP) [84–86].”
MethodCiclopirox Olamine 1% Cream A Preliminary Review of its Antimicrobial Activity and Therapeutic Use
Jue, S. G., Dawson, G. W., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198529040-00002 · Cited by 95
Kim, H. U., Kim, T. Y., & Lee, S. Y. (2009) · Molecular BioSystems · doi:10.1039/b916446d · Cited by 94
Loui, C., Chang, A. C., & Lu, S. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-183 · Cited by 92 · cited 5×
“Chloramphenicol served as a positive control because it sensitizes cells to H2O2 [29].”
BackgroundInfluentialNakao, R., Senpuku, H., & Watanabe, H. (2006) · Infection and Immunity · doi:10.1128/iai.00261-06 · Cited by 91 · cited 1×
“readily form biofilms compared to the parental strain [60].”
BackgroundBoyd, L. B., Maynard, M. J., Morgan‐Linnell, S. K., Banks, L. D., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J. A., Steffen, D. L., & Zechiedrich, L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00722-08 · Cited by 85
Self-citationRoss, K. L., Davis, C. N., & Fridovich‐Keil, J. L. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.07.005 · Cited by 80 · cited 1×
“GAL10 can also epimerize acetylated UDPgalactose and UDP-glucose [65].”
BackgroundDeng, L., Sundriyal, S., Rubio, V., Shi, Z.-Z., & Song, Y. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012592 · Cited by 65 · cited 1×
“To identify new antimicrobial agents with novel targets, our effort in targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) yielded an N-hydroxypyridinone compound that shows broad-spectrum antibacterial activity [9].”
BackgroundSelf-citationCellular stress created by intermediary metabolite imbalances
Lee, S. J., Trostel, A. N., Le, P., Harinarayanan, R., FitzGerald, P. C., & Adhya, S. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910586106 · Cited by 62 · cited 7×
“coli to either catabolize galactose or to generate the nucleotide-charged substrates, UDP-galactose or UDP-glucose, depending on cellular needs [35,58].”
BackgroundMethodInfluentialHo, T. D., & Waldor, M. K. (2007) · Infection and Immunity · doi:10.1128/iai.01342-06 · Cited by 62 · cited 2×
“the ability of the mutant to colonize the intestines of rabbits, increases its sensitivity to host-derived antimicrobial polypeptides, and increases its sensitivity to bacteriophage P1 [46].”
BackgroundSigle, H.-C., Thewes, S., Niewerth, M., Korting, H. C., Schäfer-Korting, M., & Hube, B. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki089 · Cited by 58 · cited 4×
“Together these data formed the basis for the model that ciclopirox olamine inhibits cells through general iron chelation, but that oxygen accessibility and additional iron-independent mechanisms may also influence ciclopirox olamine efficacy [10,18].”
BackgroundResultInfluentialSpecialized Sugar Sensing in Diverse Fungi
Brown, V., Sabina, J., & Johnston, M. (2009) · Current Biology · doi:10.1016/j.cub.2009.01.056 · Cited by 52
Monitoring Surface Chemical Changes in the Bacterial Cell Wall
Ramstedt, M., Nakao, R., Wai, S. N., Uhlin, B. E., & Boily, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209536 · Cited by 51 · cited 3×
“the lack of phosphorylation affects overall membrane charge and surface hydrophobicity [41].”
BackgroundInfluentialRepurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii
Chopra, S., Torres-Ortiz, M., Hokama, L. A., Madrid, P. B., Tanga, M. J., Mortelmans, K. E., Kodukula, K., & Galande, A. K. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq353 · Cited by 51 · cited 5×
“coli; however, the antibiotic resistance status for the tested bacteria was not indicated [8,10,20].”
BackgroundMethodInfluentialThe Possible Mechanism of Action of Ciclopirox Olamine in the Yeast Saccharomyces cerevisiae
Leem, S., Park, J., Kim, I.-S., Chae, J.-Y., Sugino, A., & Sunwoo, Y. (2003) · Molecules and Cells · doi:10.1016/s1016-8478(23)13707-1 · Cited by 44 · cited 1×
“Mutations were identified in genes encoding proteins involved in DNA replication, DNA repair, cellular transport, oxidative stress, and signal transduction [16].”
BackgroundSingh, V., Satheesh, S. V., Mysore, R., & Sadhale, P. P. (2006) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2006.11.006 · Cited by 44 · cited 3×
“Whereas ScGAL10 and CaGAL10 are both essential for growth when galactose is the sole carbon source, only CaGAL10 has additional functions to maintain cell-wall integrity and cell morphology, respond to oxidative stress, and proceed through normal hyphal morphogenesis in the absence of galactose [49].”
BackgroundUrbaniak, M. D., Tabudravu, J. N., Msaki, A., Matera, K. M., Brenk, R., Jaspars, M., & Ferguson, M. A. J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.091 · Cited by 44
Weir, S. J., Patton, L., Castle, K., Rajewski, L. G., Kasper, J., & Schimmer, A. D. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01172.x · Cited by 42 · cited 2×
“Additionally, ciclopirox is currently in a Phase I clinical trial for treatment of multiple myeloma [14,15].”
BackgroundRole of galE on biofilm formation by Thermus spp.
Niou, Y.-K., Wu, W., Lin, L., Yu, M.-S., Shu, H., Yang, H., & Lin, G.-H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.120 · Cited by 40 · cited 3×
“GalE enzymatic activity was assessed as previously published [31,32].”
BackgroundMethodMode of Action of 6-Cyclohexyl-l-hydroxy-4-methyl-2(1H)-pyridone Ethanolamine Salt (Hoe 296)
Sakurai, K., Sakaguchi, T., Yamaguchi, H., & Iwata, K. (2009) · Chemotherapy · doi:10.1159/000237762 · Cited by 38 · cited 1×
“albicans have shown that ciclopirox alters the structure of cell membranes [17,49,50].”
BackgroundHOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results.
Dittmar, W., & Lohaus, G. (1973) · PubMed · Cited by 32
Cloning, expression and characterization of a UDP-galactose 4-epimerase from Escherichia coli
Chen, X., Kowal, P., Hamad, S., Fan, H., & Wang, P. G. (1999) · Biotechnology Letters · doi:10.1023/a:1005678225031 · Cited by 29 · cited 1×
“Although this assay does not address the possibility that ciclopirox may affect GalE epimerization of UDP-glucose into UDPgalactose, this reaction is less favored [33].”
BackgroundCiclopirox protects mitochondria from hydrogen peroxide toxicity
Lee, S. J., Jin, Y. N., Yoon, H. Y., Choi, B., Kim, H., Oh, Y., Kim, H., & Kim, W. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706206 · Cited by 29 · cited 1×
“Indeed, others have suggested repurposing ciclopirox as an anti-human immunodeficiency virus drug [11], an agent to protect against mitochondrial damaged cells [12], and a way to enhance diabetic wound healing [13].”
BackgroundKo, S. H., Nauta, A., Morrison, S. D., Zhou, H., Zimmermann, A. S., Gurtner, G. C., Ding, S., & Longaker, M. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027844 · Cited by 27 · cited 2×
“It has already been shown that ciclopirox olamine applied topically to wounds induces angiogenesis and promotes faster wound healing [13].”
BackgroundAberrant sialylation of granulocyte membranes in chronic myelogenous leukemia
Baker, M., Rn, T., Whelton, C., & Hindenburg, A. (1984) · Blood · doi:10.1182/blood.v63.5.1194.1194 · Cited by 27 · cited 1×
“In chronic myelogenous leukemia cells and in breast cancer MCF-7 cells, there is an increase in a3sialytranserase activity, which produces shorter, sialylated Oglycans compared to normal myeloid and breast cells [75,76].”
BackgroundReduction of virulence factor pyocyanin production in multidrug-resistant Pseudomonas aeruginosa
Fuse, K., Kikuchi, T., Gomi, K., Nukiwa, T., Fuse, K., Fujimura, S., Watanabe, A., Fuse, K., & Iida, Y. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0457-9 · Cited by 26 · cited 3×
“aeruginosa strains suffer significant lung destruction [55].”
BackgroundEthanolamine: A Signal to Commence a Host-Associated Lifestyle?
Garsin, D. A. (2012) · mBio · doi:10.1128/mbio.00172-12 · Cited by 26
Structure and Function of the d -Galactose Network in Enterobacteria
Csiszovszki, Z., Krishna, S., Orosz, L., Adhya, S. L., & Semsey, S. (2011) · mBio · doi:10.1128/mbio.00053-11 · Cited by 21
Relationship between UDP-Galactose 4′-Epimerase Activity and Galactose Sensitivity in Yeast
Wasilenko, J. L., & Fridovich‐Keil, J. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600778200 · Cited by 19 · cited 1×
“albicans and other eukaryotic cells [49,66,67].”
Physicochemical studies on Ciclopirox olamine complexes with divalent metal ions
Tarawneh, R., Hamdan, I. I., Bani-Jaber, A., & Darwish, R. M. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.009 · Cited by 14 · cited 1×
“Physiochemical studies showed that ciclopirox forms metal complexes with Mg, Ca, Cu, Fe, Zn, and Mn and that these complexes display a wide range of water solubility and lipophilicity [25].”
BackgroundBraga, P. C., Piatti, G., Conti, E., & Vignali, F. (1992) · PubMed · Cited by 13
Porins and lipopolysaccharide of Escherichia coli ATCC 25922 and isogenic rough mutants
Rivera, M., Bertasso, A., McCaffrey, C., & Georgopapadakou, N. H. (1993) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1993.tb06096.x · Cited by 12 · cited 1×
“Of the LPS bands characteristic of the ATCCH 25922 isolate [52], ciclopirox reduced the concentrations of the highest molecular weight band (,20 kDa) as well as the O-antigen bands (37–50 kDa), as indicated by the arrows (Figure 6).”
BackgroundSilvia, A., Rocha, J., & Leitão, J. H. (2011) · InTech eBooks · doi:10.5772/19649 · Cited by 7
Ji, S. C., Wang, X., Yun, S. H., Jeon, H. J., Lee, H. J., Kim, H.-J., & Lim, H. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017646 · Cited by 4 · cited 2×
“During early to late logarithmic growth phase, 70% of the galETKM transcripts are synthesized from the P1 promoter and all four genes are made [35,57].”
Background
Cited by
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
The challenge of converting Gram‐positive‐only compounds into broad‐spectrum antibiotics
Richter, M. F., & Hergenrother, P. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13598 · Cited by 227
Boyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections
Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., GarcÃa-Contreras, S. J., & GarcÃa-Contreras, R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00282 · Cited by 168
“For P. aeruginosa, ciclopirox inhibits pyocyanin and may increase pyoverdine production (Carlson-Banning et al., 2013).”
BackgroundMethodInfluential
Metadata
- Authors
- Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L.
- Affiliations
- Baylor College of Medicine (US)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Zechiedrich, Lynn
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-07-23
- Volume
- 8
- Issue
- 7
- Pages
- e69646
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3720592
- OpenAlex
- W2023096091
- Cited by
- 73
- References
- 87
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 12 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 6 · 2014: 1
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health (NIH T32, NIH-R01, T32 AI55413)
- National Institute of Allergy and Infectious Diseases (T32 AI55413, R01AI054830, R21AI088123, T32AI055413)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- ciclopirox, drug repurposing, antibiotic resistance, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, gales, UDP-glucose 4-epimerase, galactose metabolism, lipopolysaccharide biosynthesis, galU, multidrug-resistant Gram-negative bacteria, minimum inhibitory concentration
- MeSH terms
- Ciclopirox, Anti-Bacterial Agents, Ciprofloxacin, Drug Resistance, Microbial, Escherichia coli, Galactose, Humans, Hydrogen Peroxide, Iron, Klebsiella pneumoniae, Lipopolysaccharides, Microbial Sensitivity Tests, Mutation, Phenotype, Pyridones, Drug Resistance, Bacterial, Escherichia coli Proteins, Acinetobacter baumannii, Microbial Viability, Biosynthetic Pathways, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.